Budget impact analysis for the Health Care Package by using MammaPrint in Belgium
Publication: ESMO BREAST CANCER CONGRESS 2022 Authors De Lameillieure Read More
Equivalence of NGS-based MammaPrint 70-gene signature risk of recurrence and BluePrint 80-gene signature of molecular subtyping tests to the centralized microarray tests
Publication: ESMO BREAST CANCER CONGRESS 2022AuthorsEsther Schuler(1), Sahra Uygun(2), Lorenza Read More
Agendia Demonstrates Accessibility and Affordability of MammaPrint and BluePrint in Europe at ESMO Breast Cancer 2022
Next-generation sequencing version of MammaPrint and BluePrint enables decentralized testing Read More
Agendia Appoints Farida Peters-Abbadi as Vice President of Marketing
Strategic hire underscores commitment to commercial growth across genomic assay Read More
Agendia Appoints Elizabeth Hanna as Executive Vice President and Chief Commercial Officer, Bolsters Company’s Global Market Growth Strategy
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – March 15, 2022 Read More
GenomeWeb – Agendia Offering AI-Enabled Genomic Test for Breast Cancer in Brazil as it Eyes Global Market
January 27, 2022 By Leo O’Connor NEW YORK ─ As part Read More
Agendia Study Demonstrates MammaPrint® and BluePrint® Capture Full Spectrum of Early Breast Cancer Biology, Providing Opportunity for Highly Individualized Treatment
New analysis in peer-reviewed journal Genes, Chromosomes and Cancer Read More
Agendia stärkt patientennahe Brustkrebs-Versorgung in Deutschland durch Kooperation mit Speziallabor ZOTZ | KLIMAS
Weitere Kooperation mit zertifiziertem Speziallabor Mehr Informationen für individuelle Therapien Read More
Agendia to Provide First Digital MammaPrint Capability to Brazil
AI solution will expand Agendia’s testing platform in the Brazilian Read More
Agendia Partners with Illumina to Expand Genomic Testing in Breast Cancer Care
Multi-year partnership to advance the use of next-generation sequencing for Read More
